Stock News•2 weeks ago
Praxis Precision Medicines: Priced For Half Of What I Think It's Worth
Praxis Precision Medicines' stock is trading at half the analyst's estimated intrinsic value, based on pipeline prospects.
MarketLens
Is Protagenic Therapeutics (PTIX) Poised for a Breakthrough in Neuropsychiatric Treatment
3 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•1 months ago
AtaiBeckley: BPL-003's Promising Potential On TRD Keeps Me Bullish
ATAI's BPL-003 advances to Phase 3 trials for treatment-resistant depression (TRD) with topline data expected by early 2029, while VLS-01 offers a nearer Q4 2026 catalyst.
Stock News•2 months ago
The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade
NeOnc Technologies advances neuro-oncology therapies targeting glioblastoma and other brain cancers, potentially making brain cancer treatment one of the decade's biggest biotech stories.
Stock News•2 months ago
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
Protagenic Therapeutics (OTCQB:PTIX) engaged Floyd Regulatory Strategic Consulting and Danforth Health to support the clinical development of its lead candidate, PT00114. These partnerships aim to acc...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•2 hours ago
Apple CEO Tim Cook Just Passed His Successor a Mess
Stock News•2 hours ago
MSFT DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Microsoft Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – MSFT
Stock News•3 hours ago
Alphabet's Cloud Computing Business Just Posted 82% Revenue Growth. Next Quarter Could Be Even Better.
Stock News•5 hours ago
Sundar Pichai's Alphabet Has Grown Google Cloud Revenue 82% Year Over Year. Here's Why That Growth Rate Justifies the Company's Capex Bet.
Stock News•5 hours ago